Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
de Groot, Stefanie, Pijl, Hanno, Charehbili, Ayoub, van de Ven, Saskia, Smit, Vincent T. H. B. M., Meershoek-Klein Kranenbarg, Elma, Heijns, Joan B., van Warmerdam, Laurence J. C., Kessels, Lonneke W.Volume:
21
Language:
english
Journal:
Breast Cancer Research
DOI:
10.1186/s13058-019-1180-6
Date:
December, 2019
File:
PDF, 1.03 MB
english, 2019
File converter
More search results
More benefits 
